Shobha J C, Kumar T R, Raju B S, Kamath S, Rao M, Babu A, Bhaduri J
Dept. of Clinical Pharmacology and Therapeutics, NIMS, Hyderabad.
J Assoc Physicians India. 2000 May;48(5):497-500.
To study the effect of losartan potassium in the treatment of mild to moderate hypertension and to compare its efficacy and adverse effect profile with enalaparil maleate.
One hundred and forty five patients with mild to moderate essential hypertension were enrolled in this randomized, double blind, controlled, parallel and multicentric study. Seventy two patients received losartan potassium 50 mg and seventy three received enalapril maleate 5 mg.
Losartan potassium reduced the DBP to < 90 mm Hg in 59% of the patients at the end of 8 weeks compared to 45% in the enalapril maleate group. DBP was reduced by 10 or > than 10 mm Hg in 89% of the patients with losartan as compared to the baseline whereas it was 80% in the enalapril group. Percentage of side effects seen in losartan and enalapril groups were 12 and 22 respectively.
Losartan potassium is an efficacious antihypertensive agent in mild to moderate hypertension. It also has fewer side effects when compared to enalapril maleate.
研究氯沙坦钾治疗轻至中度高血压的效果，并将其疗效和不良反应情况与马来酸依那普利进行比较。
145例轻至中度原发性高血压患者参与了这项随机、双盲、对照、平行、多中心研究。72例患者服用50毫克氯沙坦钾，73例患者服用5毫克马来酸依那普利。
8周结束时，氯沙坦钾组59%的患者舒张压降至<90毫米汞柱，而马来酸依那普利组为45%。与基线相比，氯沙坦组89%的患者舒张压降低了10或>10毫米汞柱，而依那普利组为80%。氯沙坦组和依那普利组出现副作用的百分比分别为12%和22%。
氯沙坦钾是治疗轻至中度高血压的有效降压药。与马来酸依那普利相比，其副作用也较少。
